7/24/2009 | SS | Market Commentary: Bristol-Meyers predicted to continue deal pace; proxy firm sides with Foundation Coal buyout
|
11/25/2008 | CVHY | ZymoGenetics files $100 million shelf
|
6/30/2008 | PP | Market Commentary: ZymoGenetics lands loan; BofI latest bank to eye openings; Raptor closes; Groundstar plans offering
|
6/30/2008 | PP | New Issue: ZymoGenetics arranges $100 million loan with Deerfield
|
3/12/2008 | SS | Warburg Pincus could seek more representation on ZymoGenetics' board
|
11/27/2006 | SS | Ford shares, preferreds skid; Nasdaq, LSE slip; biotechs lower; Raytheon drops; Ventas falls
|
11/2/2006 | BT | Merrill puts ZymoGenetics at buy
|
11/1/2006 | BT | ZymoGenetics says net loss of $31.2 million for the quarter better than expected
|
10/31/2006 | BT | Market Commentary: Alnylam, CytRx gain with Sirna; Antigenics gains; Viragen sinks; ZymoGenetics off ahead of results
|
10/30/2006 | BT | Merrill keeps ZymoGenetics at buy
|
10/16/2006 | BT | ZymoGenetics rated at buy by Merrill
|
10/16/2006 | BT | Market Commentary: Vical up on PIPE; Amgen sinks on FDA delay; Critical up 16%; Omrix off 14.5% on profit taking
|
9/18/2006 | BT | Merrill rates ZymoGenetics at buy
|
9/18/2006 | BT | ZymoGenetics bleeding trial meets primary, secondary endpoints
|
9/6/2006 | BT | ZymoGenetics retains buy rating from Merrill
|
9/5/2006 | BT | ZymoGenetics reports positive results from phase 3 trial of rhThrombin
|
8/29/2006 | BT | ZymoGenetics at buy by Merrill
|
8/14/2006 | BT | ZymoGenetics sues Bristol-Myers for infringement of fusion protein patents
|
8/4/2006 | BT | Merrill buy rating for ZymoGenetics unchanged
|
7/25/2006 | BT | ZymoGenetics at buy by Merrill
|
7/25/2006 | BT | ZymoGenetics says atacicept studies in lupus yield promising results
|
7/12/2006 | BT | ZymoGenetics begins phase 1 trial with IL-21 and Rituxan in non-Hodgkin's lymphoma patients
|
6/26/2006 | BT | ZymoGenetics, Serono say results of TACI-Ig phase 1b trial in rheumatoid arthritis are promising
|
6/20/2006 | BT | ZymoGenetics completes enrollment for rhThrombin phase 3 trial
|
6/13/2006 | BT | ZymoGenetics plans to finish phase 3 trial of recombinant human Thrombin, file BLA this year
|
6/5/2006 | BT | ZymoGenetics: preliminary data for IL-21 in metastatic melanoma, renal cell cancer show antitumor activity
|
5/4/2006 | BT | ZymoGenetics keeps Merrill's buy rating
|
5/4/2006 | BT | ZymoGenetics reports $31.7million net loss for first-quarter, reduced revenues
|
3/31/2006 | BT | Merrill keeps ZymoGenetics at buy
|
3/31/2006 | BT | Market Commentary: NitroMed restructuring cheered; Genitope gains on MyVax data; ZymoGenetics up; Panacos off
|
2/9/2006 | BT | Merrill keeps ZymoGenetics at buy
|
1/10/2006 | BT | Merrill maintains ZymoGenetics at buy
|
1/10/2006 | BT | ZymoGenetics' rheumatoid arthritis drug induces response in phase 1 study
|
12/12/2005 | BT | ZymoGenetics says phase 1 TACI-Ig study in multiple myeloma has early, promising results
|
12/9/2005 | BT | Merrill maintains ZymoGenetics at buy
|
11/14/2005 | BT | ZymoGenetics' IL-21 found to produce anti-tumor activity in skin cancer patients
|
11/3/2005 | BT | Merrill maintains ZymoGenetics at buy
|
10/27/2005 | BT | ZymoGenetics begins phase 3 study with rhThrombin
|
10/5/2005 | BT | Market Commentary: Human Genome stock falls 29%, convertibles lose outright, up on swap; Vertex slides on profit taking
|
10/5/2005 | BT | ZymoGenetics' orphan status a plus, Merrill says
|
8/8/2005 | BT | ZymoGenetics price target cut by Merrill
|
8/4/2005 | BT | Market Commentary: ZymoGenetics follow-on upsized but discounted; Eli Lilly sells $1.5 billion variable floaters
|
8/4/2005 | BT | New Issue: ZymoGenetics raises $135 million in upsized follow-on at $18, discounted from $18.39 close
|
8/2/2005 | BT | Market Commentary: Anadys up on Novartis details; Ariad, Nastech, ZymoGenetics mixed; Myogen zooms; Isis gains
|
8/1/2005 | BT | Market Commentary: Anadys, Ariad, Nastech offerings join ZymoGenetics for this week; Amgen, Abgenix up on fast track
|
7/29/2005 | BT | Market Commentary: Advanced Life Sciences, Avalon IPOs delayed; ZymoGenetics on deck for Wed; stem cell names rise
|
7/28/2005 | BT | Market Commentary: Advanced Life Sciences IPO cut; ZymoGenetics plans follow-on; Elan plunges on credit worries
|
7/28/2005 | BT | ZymoGenetics plans follow-on offering of 6.5 million shares
|
7/19/2005 | BT | Zymogenetics initiated by Global Crown at neutral
|
6/17/2005 | BT | Zymogenetics files $200 million stock shelf
|
10/15/2004 | PP | New Issue: Zymogenetics sells $50 million stock to Serono as part of agreements
|